LCTX

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2001, for BioTime, Inc. (Note: The input metadata referenced "Lineage Cell Therapeutics," but the filing text explicitly identifies the registrant as BioTime, Inc.). BioTime is a development-stage biomedical company focused on researching and developing synthetic plasma expanders, blood volume substitutes, and organ preservation solutions. Its lead product, Hextend, is licensed to Abbott Laboratories for the U.S. and Canada and to Horus B.V. for international markets (excluding the U.S., Canada, and Japan).

Key Financial Metrics

Debt and Liquidity: As of March 31, 2001, the company had no outstanding debt. However, it entered into a Revolving Line of Credit Agreement in March 2001 allowing it to borrow up to $1,000,000. No amounts were drawn as of the reporting date. The company holds $321,512 in cash, a significant decrease from $1,318,338 at the end of 2000.

Material Changes vs. Prior Period

• Revenue Growth: Royalty revenue increased to $32,695 in Q1 2001 from $5,732 in Q1 2000. This revenue reflects royalties on sales made by Abbott during the fourth quarter of 2000, as the company recognizes revenue upon receipt of sales reports rather than when sales occur.
• Expense Reduction: Net loss decreased to $951,739 from $1,319,947 in the prior year quarter. This improvement was driven primarily by a reduction in Research and Development (R&D) expenses, which fell to $553,892 from $909,930 due to the absence of clinical trials in Q1 2001.
• Cash Position: Cash and cash equivalents declined by approximately $1 million during the quarter, dropping from $1.32 million to $321,512, primarily due to operating cash outflows.

Guidance, Outlook, and Risks

Outlook and Management Commentary: BioTime expects to receive an initial license fee of $4,000,000 from Horus B.V. upon confirmation of manufacturing and supply arrangements, though this payment had not been received as of March 31, 2001. The company anticipates additional license fees of up to $5,500,000 from Horus upon achieving specific milestones. Management expects Hextend sales to grow as Abbott expands its marketing efforts and secures more hospital formulary approvals. The company is also advancing clinical trials for PentaLyte and developing HetaCool for low-temperature surgery.

Risks and Contingencies:

• Liquidity Risk: The company requires additional funding to continue operations and clinical trials. Failure to secure the Horus license fee or additional financing could force the company to curtail operations.
• Regulatory Risk: Future profitability depends on obtaining regulatory approvals (FDA and foreign) for its products.
• Revenue Recognition Timing: Revenue is recognized with a lag (quarterly reports from licensees), creating volatility in reported quarterly results.
• Development Stage: The company has incurred cumulative losses of over $28 million since inception and has no assurance it will achieve profitable operations.

Key Facts for Investor Verification

• Verify the status of the $4,000,000 license fee from Horus B.V., which is contingent on manufacturing arrangements and had not been received as of March 31, 2001.
• Confirm the cash runway given the current cash balance of ~$321,000 and monthly burn rate implied by the quarterly operating cash outflow of ~$1 million.
• Monitor the utilization of the $1,000,000 line of credit with Alfred D. Kingsley, which carries a 10% interest rate and requires repayment upon receipt of $2,000,000 in capital or fees.
• Track regulatory milestones for Hextend in Canada and Europe, as well as the Phase I completion and Phase II planning for PentaLyte.
• Review the timing of royalty recognition, as Q1 2001 revenue reflects Q4 2000 sales, meaning Q2 2001 revenue will reflect Q1 2001 sales.